Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by macman1519on Mar 27, 2018 2:24pm

105 Views

Post# 27788620

RE:RE:RE:RE:Not just a fluke "specific cannabinoid"

What it appears to you, clueless, is irrelevant. They got the weed from somebody, probably the company they are discussing terms with, and i will bet you they are close to finalyzing a deal, clueless. U were wrong on the pp, now ur minimizing the jv, lol such weak stuff u have, clueless!!!

bionicjoe wrote:

Quattro74 wrote: My guess is they are in talks with a Canabis company, that has shown some good clinical data, to develop a joint treatment for GBM. IF this is where we get our cash infusion, fine, good thinking. Let's get it going and get our other blockbuster products out there!

I didn't get that impression. For me the PR was a general invitation to the cannabis industry in the hope that someone picks up the phone and calls. Call it a fishing trip. It appears they haven't been able to sell their brain cancer science within the biotech sector and are now appealing directly to the hot cannabis sector.